Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 76 articles: HTML format

Single Articles

September 2025
1. NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al
   Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
   Cancer. 2025;131:e70070.
   PubMed     Abstract available
   
   
   
2. NIERENGARTEN MB
   Outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated radiation therapy for localized prostate cancer.
   Cancer. 2025;131:e70013.
   PubMed    
   
   
   
3. NIERENGARTEN MB
   A persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis.
   Cancer. 2025;131:e70012.
   PubMed    
   
   
   August 2025
4. TSUNG I, Yentz SE, Reichert ZR
   Controversies in metastatic hormone-sensitive prostate cancer.
   Cancer. 2025;131:e70030.
   PubMed     Abstract available
   
   
   
5. NORIEGA ESQUIVES BS, Manoharan A, Penedo FJ, Dee EC, et al
   Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos.
   Cancer. 2025;131:e70029.
   PubMed     Abstract available
   
   
   
6. SANDERS J, Levell C, Brand LJ, Dahut WL, et al
   Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative.
   Cancer. 2025;131:e70010.
   PubMed     Abstract available
   
   
   
7. SAEED F, Berchuck JE, Bilen MA, Gandhi JS, et al
   Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
   Cancer. 2025;131:e70037.
   PubMed     Abstract available
   
   
   
8. FALAGARIO UG, Pellegrino F, Abbadi A, Bjornebo L, et al
   Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.
   Cancer. 2025;131:e70045.
   PubMed     Abstract available
   
   
   
9. GREEN-LOTT AY, Wadhwa A, Bailey AV, Kwan L, et al
   Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration.
   Cancer. 2025;131:e70007.
   PubMed     Abstract available
   
   
   
10. NIERENGARTEN MB
    Superior prostate cancer detection with LATP versus TRUS.
    Cancer. 2025;131:e35958.
    PubMed    
    
    
    July 2025
11. GRANT RS, Kakani P, Movva P, Daskivich TJ, et al
    Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.
    Cancer. 2025;131:e35968.
    PubMed     Abstract available
    
    
    June 2025
12. NIERENGARTEN MB
    Acute toxicity of prostate cancer radiotherapy associated with late toxicity: Acute toxicity following prostate cancer radiotherapy was statistically and significantly associated with late toxicity in patient-reported quality-of-life metrics.
    Cancer. 2025;131:e35886.
    PubMed    
    
    
    
13. GINSBURG KB, Sessine MS, Bock CH, Goodman M, et al
    Factors associated with switching from active surveillance to treatment in men with low-risk prostate cancer: A population-based study.
    Cancer. 2025;131:e35909.
    PubMed     Abstract available
    
    
    May 2025
14. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    PubMed     Abstract available
    
    
    April 2025
15. LAWRENCE WR, Freedman ND, McGee-Avila JK, Hong HG, et al
    Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival.
    Cancer. 2025;131:e35850.
    PubMed     Abstract available
    
    
    
16. FUKUOKAYA W, Mori K, Yanagisawa T, Urabe F, et al
    Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.
    Cancer. 2025;131:e35819.
    PubMed     Abstract available
    
    
    March 2025
17. SEBASTIAN NT, Patil D, Patel PR, Jani AB, et al
    Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
    Cancer. 2025;131:e35795.
    PubMed     Abstract available
    
    
    
18. NIERENGARTEN MB
    Higher rates of long-term complications after prostate cancer treatment.
    Cancer. 2025;131:e35761.
    PubMed    
    
    
    
19. NIERENGARTEN MB
    Reduced long-term side effects with MRI-guided radiotherapy in prostate cancer.
    Cancer. 2025;131:e35762.
    PubMed    
    
    
    February 2025
20. NIERENGARTEN MB
    Healthy diet may reduce the risk of low-grade prostate cancer progressing to a higher grade.
    Cancer. 2025;131:e35740.
    PubMed    
    
    
    January 2025
21. CASTANEDA P, Kuhlmann PK, Ithisuphalap J, Howard LE, et al
    Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
    Cancer. 2025;131:e35684.
    PubMed     Abstract available
    
    
    
22. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    PubMed     Abstract available
    
    
    December 2024
23. MUKAND NH, Chirikova E, Lichtensztajn D, Negoita S, et al
    Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.
    Cancer. 2024;130:4298-4305.
    PubMed     Abstract available
    
    
    
24. SAYAN M, Chen MH, Wu J, Leeman JE, et al
    Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial.
    Cancer. 2024 Dec 4. doi: 10.1002/cncr.35674.
    PubMed     Abstract available
    
    
    
25. BRYCE AH, Agarwal N, Beltran H, Hussain MH, et al
    Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
    Cancer. 2024 Dec 1. doi: 10.1002/cncr.35612.
    PubMed     Abstract available
    
    
    November 2024
26. SRIVASTAVA A, Liu X, Maganty A, Kaufman SR, et al
    Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.
    Cancer. 2024 Nov 5. doi: 10.1002/cncr.35633.
    PubMed     Abstract available
    
    
    
27. SOERENSEN SJC, Lim DS, Montez-Rath ME, Chertow GM, et al
    Pesticides and prostate cancer incidence and mortality: An environment-wide association study.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35572.
    PubMed     Abstract available
    
    
    October 2024
28. NIERENGARTEN MB
    Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer.
    Cancer. 2024;130:3399.
    PubMed    
    
    
    
29. MOUSA A, Nguyen DD, Lalani AK, Satkunasivam R, et al
    Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
    Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606.
    PubMed     Abstract available
    
    
    
30. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality.
    Cancer. 2024 Oct 8. doi: 10.1002/cncr.35563.
    PubMed     Abstract available
    
    
    September 2024
31. ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al
    Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
    Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568.
    PubMed     Abstract available
    
    
    
32. KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al
    Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498.
    PubMed     Abstract available
    
    
    
33. 
    Addition of apalutamide to ADT after radical prostatectomy offers encouraging results.
    Cancer. 2024;130:2896.
    PubMed    
    
    
    
34. NIERENGARTEN MB
    Optimal timing of radiotherapy after radical prostatectomy points to salvage radiotherapy for PSA failure.
    Cancer. 2024;130:2895.
    PubMed    
    
    
    August 2024
35. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    PubMed     Abstract available
    
    
    July 2024
36. MORGANS AK
    Optimizing assessments of quality of life in contemporary prostate cancer clinical trials.
    Cancer. 2024 Jul 27. doi: 10.1002/cncr.35485.
    PubMed    
    
    
    
37. LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al
    Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472.
    PubMed     Abstract available
    
    
    
38. MEAGHER M, Morgan K, Deshler L, Riviere P, et al
    Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469.
    PubMed     Abstract available
    
    
    
39. SANYAL C, Ragavan MV
    Beyond the PSA: The hidden costs of screening in prostate cancer.
    Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474.
    PubMed    
    
    
    
40. NIERENGARTEN MB
    Novel hormone is safe and effective in men receiving radiotherapy for prostate cancer.
    Cancer. 2024;130:2408.
    PubMed    
    
    
    
41. SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al
    Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
    Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392.
    PubMed     Abstract available
    
    
    
42. GONG J, Janes JL, Trustram Eve C, Stock S, et al
    Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
    Cancer. 2024 Jul 1. doi: 10.1002/cncr.35466.
    PubMed     Abstract available
    
    
    June 2024
43. MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al
    Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438.
    PubMed     Abstract available
    
    
    
44. BASARIA S, Taplin ME, McDonnell M, Simonson DC, et al
    Insulin resistance during androgen deprivation therapy in men with prostate cancer.
    Cancer. 2024 Jun 16. doi: 10.1002/cncr.35443.
    PubMed     Abstract available
    
    
    
45. PAGADALA MS, Lui A, Lynch J, Karunamuni R, et al
    Healthy lifestyle and prostate cancer risk in the Million Veteran Program.
    Cancer. 2024 Jun 12. doi: 10.1002/cncr.35434.
    PubMed     Abstract available
    
    
    
46. LABBAN M, Stone BV, Steele GL, Salinas KE, et al
    A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366.
    PubMed     Abstract available
    
    
    May 2024
47. TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al
    Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
    PubMed     Abstract available
    
    
    April 2024
48. BENADADA F, Saad F, Delouya G, Taussky D, et al
    Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries.
    Cancer. 2024;130:1019-1024.
    PubMed     Abstract available
    
    
    March 2024
49. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
    A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
    PubMed     Abstract available
    
    
    
50. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
    High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
    Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
    PubMed     Abstract available
    
    
    
51. LIM FAT G, Alibhai S
    Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
    PubMed    
    
    
    
52. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    PubMed     Abstract available
    
    
    February 2024
53. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    PubMed     Abstract available
    
    
    
54. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    PubMed     Abstract available
    
    
    
55. WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al
    The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241.
    PubMed     Abstract available
    
    
    
56. LOEB S, Hua Q, Bauer SR, Kenfield SA, et al
    Plant-based diet associated with better quality of life in prostate cancer survivors.
    Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172.
    PubMed     Abstract available
    
    
    
57. HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al
    Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221.
    PubMed     Abstract available
    
    
    
58. DORFF TB, Bryce AH
    Challenges in clinical trials for high-risk but curable prostate cancer.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245.
    PubMed    
    
    
    
59. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    PubMed     Abstract available
    
    
    January 2024
60. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed     Abstract available
    
    
    
61. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    PubMed     Abstract available
    
    
    
62. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    PubMed     Abstract available
    
    
    
63. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    PubMed     Abstract available
    
    
    December 2023
64. FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al
    Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168.
    PubMed     Abstract available
    
    
    
65. 
    FDA approves new combined treatment for advanced prostate cancer.
    Cancer. 2023;129:3841-3842.
    PubMed    
    
    
    
66. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Reply to "Contextualizing racial associations in prostate cancer to expose structural causes".
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167.
    PubMed    
    
    
    
67. ROLLIN FG, Olsen E, George M
    Contextualizing racial associations in prostate cancer to expose structural causes.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157.
    PubMed    
    
    
    
68. GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al
    The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Cancer. 2023;129:3790-3796.
    PubMed     Abstract available
    
    
    November 2023
69. YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al
    Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
    Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133.
    PubMed     Abstract available
    
    
    
70. NIERENGARTEN MB
    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.
    PubMed    
    
    
    
71. BRAWLEY OW, Ramalingam R
    The enigma of race and prostate cancer.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032.
    PubMed    
    
    
    
72. LEE KM, Bryant AK, Lynch JA, Robison B, et al
    Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979.
    PubMed     Abstract available
    
    
    October 2023
73. NIERENGARTEN MB
    Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities.
    Cancer. 2023;129:3192.
    PubMed    
    
    
    
74. LEEMAN JE, Shin KY, Chen YH, Mak RH, et al
    Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Cancer. 2023;129:3044-3052.
    PubMed     Abstract available
    
    
    September 2023
75. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Racial differences in serum chemokines in prostate cancer patients.
    Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012.
    PubMed     Abstract available
    
    
    August 2023
76. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
    Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
    Cancer. 2023;129:2522-2531.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.